Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 2Myeloid 1Lymphoid 1Classical hematology 1

Conditions

Thrombocytopenia 1Leukemia, Myelogenous, Chronic, BCR-ABL Positive 1Leukemia 1

Interventions

fludarabine phosphate 113Cyclophosphamide 97Whole-Body Irradiation 82Mycophenolic Acid 79fludarabine 74Tacrolimus 69Busulfan 68Azacitidine 62Peripheral Blood Stem Cell Transplantation 59Melphalan 48Cytarabine 48Antilymphocyte Serum 47Methotrexate 45Cyclosporine 45Filgrastim 39Imatinib Mesylate 37Granulocyte Colony-Stimulating Factor 37Decitabine 35nilotinib 34thymoglobulin 31ruxolitinib 29Thiotepa 27Stem Cell Transplantation 23Clofarabine 22Alemtuzumab 21Rituximab 19Dasatinib 19Cord Blood Stem Cell Transplantation 19sargramostim 17Sirolimus 16

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Has results × oprelvekin × Myeloid × Clear all
NCT00493181 2012-02-20

Interleukin 11, Thrombocytopenia, Imatinib in Chronic Myelogenous Leukemia (CML) Patients

M.D. Anderson Cancer Center

Phase 2 Completed
8 enrolled 3 charts
Classical hematologyMyeloidOther hematologic neoplasm

Leukemia, Thrombocytopenia, Leukemia, Myelogenous, Chronic, BCR-ABL Positive

Data powered by HemOnc (CC BY 4.0) Colophon âš¡